Loading...
Intensity Therapeutics Q4 2024 Earnings Report
Intensity Therapeutics reported its full-year 2024 financial results and provided a corporate update.
Key Takeaways
Intensity Therapeutics reported a net loss of $16.3 million for the year ended December 31, 2024, an increase from a net loss of $10.5 million in the prior year. Research and development expenses significantly increased due to the progression of the INVINCIBLE-3 and INVINCIBLE-4 studies, while cash and cash equivalents stood at $2.6 million.
Research and development expenses increased to $10.5 million in 2024 from $4.8 million in 2023, primarily driven by the INVINCIBLE-3 and INVINCIBLE-4 studies.
General and administrative expenses rose to $6.1 million in 2024 from $3.5 million in 2023, due to higher salaries, benefits, stock-based compensation, and legal/consulting fees.
The company's net loss for the year ended December 31, 2024, was $16.3 million, compared to a net loss of $10.5 million in the previous year.
As of December 31, 2024, Intensity Therapeutics had $2.6 million in cash and cash equivalents.
Forward Guidance
Intensity Therapeutics anticipates continued progress in its clinical trials, with expected completion of enrollment for the INVINCIBLE-3 Study in the first half of 2026 and for the INVINCIBLE-4 Study by the end of the first quarter of 2026.
Positive Outlook
- Expects to complete enrollment in the INVINCIBLE-3 Study in the first half of 2026.
- Anticipates activating additional sites in Switzerland and France for the INVINCIBLE-4 Study in the first half of 2025.
- Aims to complete enrollment for the INVINCIBLE-4 Study by the end of the first quarter of 2026.
- Believes in the potential of INT230-6 to positively impact metastatic sarcoma and presurgical breast cancer patients.
- Actively enrolling patients across the US, Canada, Europe, and Australia for the INVINCIBLE-3 Study.
Challenges Ahead
- Requires additional funding before generating revenues from product sales.
- Subject to risks related to the initiation, timing, progress, and results of future preclinical studies and clinical trials.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...